推荐活动

专注生物医药求职招聘

CSCO大会更新四大指南,发布八大新指南,对癌症靶向药物的使用有了更明确的指导。

首页 » 产业 » 行业 2018-05-11 医世象 赞(2)
分享: 
导读
2018年4月22日,万众瞩目的2018中国临床肿瘤学会(CSCO)指南大会于南京圆满落幕。本次CSCO大会共更新四大指南,发布八大新指南,对癌症靶向药物的使用有了更明确的指导。

癌症靶向治疗是指通过特异性干预癌症发生、发展密切相关的分子或信号通路,对癌症进行治疗的方法。2018年4月22日,万众瞩目的2018中国临床肿瘤学会(CSCO)指南大会于南京圆满落幕。本次CSCO大会共更新四大指南,发布八大新指南,对癌症靶向药物的使用有了更明确的指导。而我国药品审评审批制度调整以后,国外获得批准的新药进入国内市场的速度明显加快。医世象根据癌症种类和药物靶点,对2016年-2018年第一季度肿瘤靶向药物在中国的上市情况进行了汇总。


注:靶向药物的命名规则通常为单克隆抗体以“mab”结尾;小分子以"ib"结尾(表明该物质具有蛋白质抑制性质);单克隆抗体又分为:嵌合人-鼠抗体以“ximab”结尾,人源化小鼠抗体为“zumab”结尾和完全人抗体“mumab”结尾。未在中国上市的药物尚无正式中文名称,文中提供的中文名为音译,仅供参考。 


肺癌靶向药


乳腺癌靶向药


结直肠癌靶向药


白血病靶向药


淋巴瘤靶向药


甲状腺癌靶向药


黑色素瘤靶向药


肾癌靶向药


胃癌靶向药


胃肠道间质瘤靶向药


肝癌靶向药


食管结合部癌靶向药


多发性骨髓瘤靶向药


胰腺癌靶向药


妇科癌症靶向药


软组织肉瘤靶向药


其他癌症靶向药


附:FDA批准的肿瘤靶向药物(截至2018年4月24日)


胃食管结合部癌:Trastuzumab (Herceptin®), ramucirumab (Cyramza®) 


膀胱癌:Atezolizumab (Tecentriq™), nivolumab (Opdivo®), durvalumab (Imfinzi™), avelumab (Bavencio®), pembrolizumab (Keytruda®)


脑癌:Bevacizumab (Avastin®), everolimus (Afinitor®)


乳腺癌:Everolimus (Afinitor®), tamoxifen (Nolvadex), toremifene (Fareston®), Trastuzumab (Herceptin®), fulvestrant (Faslodex®), anastrozole (Arimidex®), exemestane (Aromasin®), lapatinib (Tykerb®), letrozole (Femara®), pertuzumab (Perjeta®), ado-trastuzumab emtansine (Kadcyla®), palbociclib (Ibrance®), ribociclib (Kisqali®), neratinib maleate (Nerlynx™), abemaciclib (Verzenio™), olaparib (Lynparza™)


宫颈癌:Bevacizumab (Avastin®)


结直肠癌:Cetuximab (Erbitux®), panitumumab (Vectibix®), bevacizumab (Avastin®), ziv-aflibercept (Zaltrap®), regorafenib (Stivarga®), ramucirumab (Cyramza®), nivolumab (Opdivo®)


隆凸性皮肤纤维肉瘤:Imatinib mesylate (Gleevec®)


内分泌/神经内分泌肿瘤:Lanreotide acetate (Somatuline® Depot), avelumab (Bavencio®), lutetium Lu 177-dotatate (Lutathera®)


头颈部癌:Cetuximab (Erbitux®), pembrolizumab (Keytruda®), nivolumab (Opdivo®) 


胃肠道间质瘤:Imatinib mesylate (Gleevec®), sunitinib (Sutent®), regorafenib (Stivarga®)


骨巨细胞瘤:Denosumab (Xgeva®)


肾癌:Bevacizumab (Avastin®), sorafenib (Nexavar®), sunitinib (Sutent®), pazopanib (Votrient®), temsirolimus (Torisel®), everolimus (Afinitor®), axitinib (Inlyta®), nivolumab (Opdivo®), cabozantinib (Cabometyx™), lenvatinib mesylate (Lenvima®), ipilimumab (Yervoy®)


白血病:Tretinoin (Vesanoid®), imatinib mesylate (Gleevec®), dasatinib (Sprycel®), nilotinib (Tasigna®), bosutinib (Bosulif®), rituximab (Rituxan®), alemtuzumab (Campath®), ofatumumab (Arzerra®), obinutuzumab (Gazyva®), ibrutinib (Imbruvica®), idelalisib (Zydelig®), blinatumomab (Blincyto®), venetoclax (Venclexta™), ponatinib hydrochloride (Iclusig®), midostaurin (Rydapt®), enasidenib mesylate (Idhifa®), inotuzumab ozogamicin (Besponsa®), tisagenlecleucel (Kymriah®), gemtuzumab ozogamicin (Mylotarg™), rituximab and hyaluronidase human (Rituxan Hycela™)


肝癌:Sorafenib (Nexavar®), regorafenib (Stivarga®), nivolumab (Opdivo®)


肺癌:Bevacizumab (Avastin®), crizotinib (Xalkori®), erlotinib (Tarceva®), gefitinib (Iressa®), afatinib dimaleate (Gilotrif®), ceritinib (LDK378/Zykadia™), ramucirumab (Cyramza®), nivolumab (Opdivo®), pembrolizumab (Keytruda®), osimertinib (Tagrisso™), necitumumab (Portrazza™), alectinib (Alecensa®), atezolizumab (Tecentriq™), brigatinib (Alunbrig™), trametinib (Mekinist®), dabrafenib (Tafinlar®), durvalumab (Imfinzi™)


淋巴瘤:Ibritumomab tiuxetan (Zevalin®), denileukin diftitox (Ontak®), brentuximab vedotin (Adcetris®), rituximab (Rituxan®), vorinostat (Zolinza®), romidepsin (Istodax®), bexarotene (Targretin®), bortezomib (Velcade®), pralatrexate (Folotyn®), ibrutinib (Imbruvica®), siltuximab (Sylvant®), idelalisib (Zydelig®), belinostat (Beleodaq®), obinutuzumab (Gazyva®), nivolumab (Opdivo®), pembrolizumab (Keytruda®), rituximab and hyaluronidase human (Rituxan Hycela™), copanlisib hydrochloride (Aliqopa™), axicabtagene ciloleucel (Yescarta™), acalabrutinib (Calquence®)


高度微卫星不稳定性/错配修复缺陷实体瘤:Pembrolizumab (Keytruda®)


多发性骨髓瘤:Bortezomib (Velcade®), carfilzomib (Kyprolis®), panobinostat (Farydak®), daratumumab (Darzalex™), ixazomib citrate (Ninlaro®), elotuzumab (Empliciti™) 


骨髓增生异常/骨髓增殖性疾病:Imatinib mesylate (Gleevec®), ruxolitinib phosphate (Jakafi®)


神经母细胞瘤Dinutuximab (Unituxin™)


上皮型卵巢癌/输卵管癌/原发性腹膜癌:Bevacizumab (Avastin®), olaparib (Lynparza™), rucaparib camsylate (Rubraca™), niraparib tosylate monohydrate (Zejula™)


胰腺癌:Erlotinib (Tarceva®), everolimus (Afinitor®), sunitinib (Sutent®)


前列腺癌:Cabazitaxel (Jevtana®), enzalutamide (Xtandi®), abiraterone acetate (Zytiga®), radium 223 dichloride (Xofigo®), apalutamide (Erleada™)


皮肤癌:Vismodegib (Erivedge®), sonidegib (Odomzo®), ipilimumab (Yervoy®), vemurafenib (Zelboraf®), trametinib (Mekinist®), dabrafenib (Tafinlar®), pembrolizumab (Keytruda®), nivolumab (Opdivo®), cobimetinib (Cotellic™), alitretinoin (Panretin®), avelumab (Bavencio®)


软组织肉瘤:Pazopanib (Votrient®), olaratumab (Lartruvo™), alitretinoin (Panretin®)


胃癌:Pembrolizumab (Keytruda®)


系统性肥大细胞增生症:Imatinib mesylate (Gleevec®), midostaurin (Rydapt®)


甲状腺癌:Cabozantinib (Cometriq®), vandetanib (Caprelsa®), sorafenib (Nexavar®), lenvatinib mesylate (Lenvima®)


(转化医学网360zhyx.com)


评论:
评 论
共有 0 条评论

    还没有人评论,赶快抢个沙发